Project description
Antibody-based nasal sprays to protect against all influenza viruses
Respiratory infectious diseases pose a significant global health threat, spreading rapidly and complicating containment. The COVID-19 pandemic highlighted a great need for preventive measures beyond vaccines and antivirals. Supported by the European Innovation Council, the PanFlu project will develop nasal sprays based on the world’s most broadly neutralising anti-influenza antibody to enhance pandemic preparedness and global health security. This new technology uses antibodies that target highly conserved sites on the virus and prevent immune escape, offering immediate and effective protection at the site of infection. PanFlu provides a significant step towards safeguarding global health.
Objective
Respiratory infectious diseases pose a significant threat to global health, spreading rapidly and hindering containment. The COVID-19 pandemic, with over 450 million cases in two years, highlighted the need for effective preventive measures beyond vaccines and antivirals, which have notable limitations.
Leyden Labs is pioneering a groundbreaking platform to counter evolving viral threats with nasal sprays developed using the world's most broadly neutralizing anti-influenza antibody (name disclosed in the short proposal). Our technology features high-affinity binding antibodies targeting the virus to prevent immune escape, with intranasal delivery ensuring targeted protection at the infection site for enhanced efficacy and convenience.
Our primary market is EU healthcare providers, working closely with EU health authorities for effective pandemic response. Success in the EU will pave the way for global expansion, including the US market. Our nasal sprays will be available by prescription and through government partnerships, with revenue from insurance coverage and government contracts.
This innovative platform aims to significantly improve pandemic preparedness and global health security. EU funding is crucial for financial support and strategic collaborations with EU healthcare providers, positioning us as leaders in healthcare innovation. The 2024 EIC Accelerator challenge will support the development of broad-spectrum monoclonal antibody-based therapeutics, ensuring efficacy against resistant variants.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases viral diseases RNA viruses influenza
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antivirals
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC - HORIZON EIC Accelerator
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2333 BK LEIDEN
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.